After five years of unprecedented momentum, the ADC field now finds itself at an interesting inflection point. With more programs in development and greater industry prioritization than ever before, ...

Antibody-drug conjugates are receiving unrivaled attention across the biopharma sector. Fueled by Enhertu’s tumor-agnostic accelerated approval, practice changing combination results from Seagen and ...

This profile has not been claimed by the company. See reviews below to learn more or submit your own review. Firex is a line of smoke and fire safety products developed by Kidde. Firex is known for ...

Cairo – Egypt Energy and FIREX Egypt 2025 have officially commenced today at the Egypt International Exhibition Center (EIEC). Running from October 14 to 16, the 34th edition of Egypt Energy and the ...

Recycling and refilling with FIREX saves technicians time, reduces costs, and reuses up to 90% of materials. FIREX 24/7 warehouses are stocked with over 1,200 essential products, ensuring technicians ...

You may have noticed an officer standing just behind the President of India at official events, state visits, or ceremonial functions. That officer holds a very important role as an Aide-de-Camp (ADC) ...

Former Vice President Atiku Abubakar, 2023 Labour Party presidential candidate Peter Obi, former Senate President David Mark and other coalition leaders have officially adopted the African Democratic ...

If you've been stuck searching for Sector - Real Estate funds, you might want to consider passing on by Fidelity International Real Estate (FIREX) as a possibility. FIREX has a Zacks Mutual Fund Rank ...

While the race is on to develop antibody-drug conjugate (ADC) cancer treatments, so too is the competition to manufacture them. Hoping to gain an edge in the rapidly growing market are MilliporeSigma ...

Antibody-drug conjugates (ADCs) are a growing class of biotherapeutics that have transformed targeted therapy, especially in oncology. By making use of monoclonal antibodies’ specificity to deliver ...

Recent regulatory activities suggest that the understanding of TROP2-directed therapies remains muddled. TROP2-directed therapies, specifically antibody-drug conjugates (ADCs), have evolved in ...

Merck & Co. has shown off data on its ROR1-directed antibody-drug conjugate (ADC), trumpeting a 100% complete response rate but also reporting safety signals that informed the decision to take the low ...